Data collection and response assessment
Medical records were examined and separated on clinical pathologic
features and treatment histories. Data and follow-up records were
updated as of March 1, 2021. The best response to PD-1 inhibitor-based
therapy, defined as a complete or partial response and stable disease
achieved at least once during therapy, was assessed using the RECIST v
1.1 criteria. The PFS was defined from the time of treatment initiation
to clinical or radiographic progression or death. Adverse events (AEs)
were graded by the National Cancer Institute Common Terminology Criteria
for Adverse Events v5.0.